BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Doheny Eye Institute - ECPv6.15.16//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Doheny Eye Institute X-ORIGINAL-URL:https://doheny.org X-WR-CALDESC:Events for Doheny Eye Institute REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20210314T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20211107T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20220313T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20221106T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20230312T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20231105T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20240310T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20241103T090000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20230407T120000 DTEND;TZID=America/Los_Angeles:20230407T130000 DTSTAMP:20260416T002031 CREATED:20220909T203158Z LAST-MODIFIED:20221102T175007Z UID:10000200-1680868800-1680872400@doheny.org SUMMARY:Distinguished Lecture Series - Alzheimer’s Disease Landscape in The Retina DESCRIPTION:Description\nDr. Maya Koronyo-Hamaoui is Professor of Neurosurgery and Professor of Biomedical Sciences at Cedars-Sinai\, Los Angeles. Her primary research focus is on early diagnosis and immune-based therapies for Alzheimer’s disease (AD). The Koronyo-Hamaoui Laboratory has shown that the hallmark pathologies of AD\, amyloid-β protein (Aβ) plaques and neurofibrillary tangles (NFTs)\, along with inflammation and neuronal degeneration are present in the retina and mirroring brain pathology in human patients\, beginning at early stages. A unique approach has been developed in her lab to detect amyloid plaques in the retina of living animal models and patients by a noninvasive optical retinal imaging. This innovation unveils new possibilities for investigation of Alzheimer’s pathology in the retina. It may also facilitate early diagnosis and noninvasive monitoring of disease progression. URL:https://doheny.org/event/distinguished-lecture-series-maya-koronyo-hamaoui-phd-2-2/ LOCATION:Doheny Eye Institute\, 150 North Orange Grove Blvd. Rm 264\, Pasadena\, CA\, 91103\, United States CATEGORIES:Distinguished Lecture Series ATTACH;FMTTYPE=image/jpeg:https://doheny.org/wp-content/uploads/2022/08/1920_koronyomayaresearch22014-1.jpg ORGANIZER;CN="Janet DeMint & Kaustabh Ghosh%2C PhD":MAILTO:jdemint@doheny.org GEO:34.1488792;-118.1594996 X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Doheny Eye Institute 150 North Orange Grove Blvd. Rm 264 Pasadena CA 91103 United States;X-APPLE-RADIUS=500;X-TITLE=150 North Orange Grove Blvd. Rm 264:geo:-118.1594996,34.1488792 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20230407T120000 DTEND;TZID=America/Los_Angeles:20230407T130000 DTSTAMP:20260416T002031 CREATED:20220909T200927Z LAST-MODIFIED:20230315T225659Z UID:10000209-1680868800-1680872400@doheny.org SUMMARY:Distinguished Lecture Series - Maya Koronyo-Hamaoui\, PhD DESCRIPTION:Description\n \n \n \n \n \n Dr. Maya Koronyo-Hamaoui is Professor of Neurosurgery and Professor of Biomedical Sciences at Cedars-Sinai\, Los Angeles. Her primary research focus is on early diagnosis and immune-based therapies for Alzheimer’s disease (AD). The Koronyo-Hamaoui Laboratory has shown that the hallmark pathology of AD\, amyloid-β protein (Aβ) plaque\, is present in the retina of human patients beginning at early stages. A unique approach has been developed in her lab to detect plaques in the retina of live rodent models by a noninvasive optical retinal imaging. This innovation unveils new possibilities for investigation of Alzheimer’s pathology in the retina. It may also facilitate early diagnosis and noninvasive monitoring of disease progression. \nMaya Koronyo-Hamaoui and collaborators at Cedars-Sinai Medical Center including Alexander Ljubimov\, produced the most extensive analysis to date of retinal changes in people with Alzheimer’s disease. Their analysis also shows how these changes correspond to brain and cognitive changes. For more information visit Read more here URL:https://doheny.org/event/distinguished-lecture-series-maya-koronyo-hamaoui-phd-2/ LOCATION:Doheny Eye Institute\, 150 North Orange Grove Blvd. Rm 264\, Pasadena\, CA\, 91103\, United States CATEGORIES:Distinguished Lecture Series ATTACH;FMTTYPE=image/png:https://doheny.org/wp-content/uploads/2022/09/DLS-Maya-Koronyo.png ORGANIZER;CN="Janet DeMint & Kaustabh Ghosh%2C PhD":MAILTO:jdemint@doheny.org GEO:34.1488792;-118.1594996 X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Doheny Eye Institute 150 North Orange Grove Blvd. Rm 264 Pasadena CA 91103 United States;X-APPLE-RADIUS=500;X-TITLE=150 North Orange Grove Blvd. Rm 264:geo:-118.1594996,34.1488792 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20230203T120000 DTEND;TZID=America/Los_Angeles:20230203T130000 DTSTAMP:20260416T002031 CREATED:20220620T235608Z LAST-MODIFIED:20230306T220539Z UID:10000188-1675425600-1675429200@doheny.org SUMMARY:A Tale of Two Drugs: Developing Novel Therapeutics to Treat Glaucoma - Michael Fautsch\, PhD DESCRIPTION:Abstract\n \n \n \n \n \n Over the past decade\, our laboratory has focused on understanding how pharmacological agents used in glaucoma therapy lower IOP\, with the belief that understanding how IOP is lowered can lead to the identification of candidate molecules that can be utilized for future targeted therapy. Towards this goal\, we identified ATP-sensitive potassium channels and Stanniocalcin-1\, two key molecules involved in IOP regulation but with very different mechanisms of action. My talk will describe our adventure (and tribulations) in developing therapeutics\, seeing them through preclinical and safety studies\, and will discuss key steps necessary to get drugs from the bench to the bedside in an academic setting. \n \n \n \n \n \n Bio\n \n \n \n \n \n Dr. Mike Fautsch is the Joseph E. and Rose Marie Green Professor of Visual Sciences at the Mayo Clinic in Rochester\, MN. He is a molecular biologist with an active research laboratory probing the pathogenesis of glaucoma. Dr. Fautsch has devoted his research efforts to understanding the physiology of elevated intraocular pressure regulation\, which is the most prevalent and only treatable risk for the disease. Toward this understanding\, his laboratory team utilizes numerous in vitro\, ex vivo and in vivo model systems to study the molecular and cellular changes that occur in normal and glaucomatous eyes during elevated pressure\, and more recently has developed several new pressure-lowering therapeutics\, one of which is in phase 2 clinical trials. Dr. Fautsch has published nearly 120 peer-reviewed papers\, has received the Ruth Salta Young Investigator award\, the Lew Wasserman Mid-career scientist award\, obtained multiple National Eye Institute and foundational grants to support his research\, and co-chaired several international conferences on the aqueous humor outflow pathway. He earned his undergraduate degree from St. Johns University\, his PhD degree from Mayo Clinic College of Medicine\, and completed his postdoctoral fellowships from UC San Diego and Mayo Clinic College of Medicine and Science. URL:https://doheny.org/event/a-tale-of-two-drugs-developing-novel-therapeutics-to-treat-glaucoma-michael-fautsch-phd/ LOCATION:Doheny Eye Institute\, 150 North Orange Grove Blvd. Rm 264\, Pasadena\, CA\, 91103\, United States CATEGORIES:Distinguished Lecture Series ATTACH;FMTTYPE=image/jpeg:https://doheny.org/wp-content/uploads/2022/07/Michael-Fautsch-10335536.jpg ORGANIZER;CN="Janet DeMint & Kaustabh Ghosh%2C PhD":MAILTO:jdemint@doheny.org GEO:34.1488792;-118.1594996 X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Doheny Eye Institute 150 North Orange Grove Blvd. Rm 264 Pasadena CA 91103 United States;X-APPLE-RADIUS=500;X-TITLE=150 North Orange Grove Blvd. Rm 264:geo:-118.1594996,34.1488792 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20221202T120000 DTEND;TZID=America/Los_Angeles:20221202T130000 DTSTAMP:20260416T002031 CREATED:20220720T235231Z LAST-MODIFIED:20221031T231328Z UID:10000187-1669982400-1669986000@doheny.org SUMMARY:Inside Out: Relations Between the Microbiome\, Eye Health and Diabetic Retinopathy - Maria Grant\, MD\, FARVO DESCRIPTION:Abstract\n \n \n \n \n \n Diabetic retinopathy (DR) is a complex disease with increasing numbers of individuals being afflicted and treatment modalities limited. There are strong interactions between the metabolome and gut microbiota\, and both have roles in the pathogenesis of DR. Communication axes exist between the gut microbiota and the eye\, therefore\, knowing how the microbiota influences the host metabolism during health and diabetes could guide a better understanding of retinopathy pathogenesis. While considerable experimental evidence exists for a gut–eye axis from murine models of human ocular diseases\, human microbiome-metabolome studies are needed to elucidate changes in the gut microbiome at the taxonomic and functional levels that are functionally related to ocular pathology. This presentation will discuss new ways to diminish DR using genetically modified bacteria that target the renin angiotensin system and using stem cells to increase the integrity of the gut barrier. \n \n \n \n \n \n Bio\n \n \n \n \n \n Dr. Grant is the Eivor and Alston Callahan\, M.D.\, Endowed Chair in Ophthalmology at the University of Alabama\, Birmingham and a Fellow of ARVO. She is globally known for her discoveries related to the functional processes of stem cells (hematopoietic\, embryonic\, and induced pluripotent) and their potential to prevent or repair vascular degeneration in retinopathies associated with diabetes and hypoxia. More recently\, her work has focused on understanding the gut-eye axis\, particularly the link between gut barrier function and disruption of the blood retinal barrier in diabetes. Dr Grant’s research is currently funded by five R01 grants from NEI/NIH while her work has also been supported by the Juvenile Diabetes Research Foundation and the American Heart Association. Her prolific publication record includes over 260 peer-reviewed research articles and 12 reviews and book chapters that have been cited over 21\,000 times. She has also given more than 80 invited lectures about her work all over the world. Dr Grant has been involved with 10 clinical trials related to the treatment of diabetic complications and currently has 13 issued and pending US and international patents. She currently serves on the Editorial Board of IOVS and American Heart Journal Plus: Cardiology Research and Practice. Dr Grant earned her undergraduate and medical degrees from the University of Florida\, Gainesville\, and completed her research fellowships from the University of Florida and the Johns Hopkins University. URL:https://doheny.org/event/inside-out-relations-between-the-microbiome/ LOCATION:Doheny Eye Institute\, 150 North Orange Grove Blvd. Rm 264\, Pasadena\, CA\, 91103\, United States CATEGORIES:Distinguished Lecture Series ATTACH;FMTTYPE=image/jpeg:https://doheny.org/wp-content/uploads/2022/07/maria-grant.jpg ORGANIZER;CN="Janet DeMint & Kaustabh Ghosh%2C PhD":MAILTO:jdemint@doheny.org GEO:34.1488792;-118.1594996 X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Doheny Eye Institute 150 North Orange Grove Blvd. Rm 264 Pasadena CA 91103 United States;X-APPLE-RADIUS=500;X-TITLE=150 North Orange Grove Blvd. Rm 264:geo:-118.1594996,34.1488792 END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20221007T120000 DTEND;TZID=America/Los_Angeles:20221007T130000 DTSTAMP:20260416T002031 CREATED:20220720T233836Z LAST-MODIFIED:20220928T142454Z UID:10000186-1665144000-1665147600@doheny.org SUMMARY:Distinguished Lecture Series - OCT Angiography and Beyond DESCRIPTION:Abstract\n \n \n \n \n \n Optical coherence tomographic angiography (OCTA) is the most important new clinical OCT technology in the past decade. It became available as a clinical instrument in 2014. Since then it has been applied to a wide range of retinal and optic nerve diseases. This presentation will review the current state of the art and key clinical applications. I will also report on the development of several novel OCT technologies in our laboratory that may have important clinical applications in the near future. \n\n One of the important recent advances in OCTA was the development of algorithms to reduce projection artifacts. Projection-resolved OCTA allows visualization of 4 distinct retinal vascular plexuses and improves the diagnosis and classification of optic nerve diseases that primarily affect the superficial plexuses\, outer retinal diseases that primarily affect the deeper plexuses\, and vascular diseases that affect all plexuses. \n\nOne killer app for OCTA is imaging of choroidal neovascularization (CNV). OCTA can visualize CNV below the retinal pigment epithelium better than fluorescein angiography (FA). It is now common to detect CNV that is invisible on FA and shows no retinal fluid accumulation on structural OCT. It may be important to monitor the vessel area of these nonexudative CNV\, which often experience rapid geometric growth prior to the development of exudation and vision loss. In some diseases such as central serous chorioretinopathy (CSR)\, OCTA is useful in distinguishing fluid accumulation due to CSR versus secondary CNV. \n\nThe evaluation of diabetic retinopathy is another emerging application for OCTA. OCTA is able to quantify macular and foveal ischemia\, which may serve as prognostic and pharmocodynamic marker for emerging treatments. OCTA can detect preretinal neovascularization with high sensitivity and measure their vessel area. Widefield OCTA may be useful in the early detection of proliferative diabetic retinopathy and monitoring of treatment efficacy. \n\nUltrawide-field OCT can image almost the entire retina or the ocular surface. Applications in retinopathy of prematurity\, peripheral retinal pathologies\, and corneoscleral topography will be discussed. On the other end of the spatial scale\, OCT microscopy using short wavelength light (i.e. blue or green) can visualize very small structures such as bacteria and collagen lamellae. Early in vitro results will be shown. Finally\, novel contrasts such as directional OCT and OCT oximetry are progressing toward clinical application. Preliminary results in human and rodents will be shown.\n \n \n \n \n \n Bio\n \n \n \n \n \n Dr. Huang is the Associate Director and Director of Research of Casey Eye Institute\, and the Peterson Professor of Ophthalmology and Professor of Biomedical Engineering at the Oregon Health & Science University. He leads the Center for Ophthalmic Optics and Lasers (www.COOLLab.net) that conducts research on topics ranging from the development of novel instrumentation and algorithms to clinical studies in a wide variety of ophthalmic and neurological diseases. Dr. Huang is globally known for his innovations in applying laser and optical technology to eye diseases. He is a co-inventor of optical coherence tomography (OCT)\, a commonly used ophthalmic imaging technology with 30 million procedures performed annually worldwide. His seminal article on OCT\, published in Science in 1991\, has been cited more than 17\,000 times. He has 38 issued US patents in the areas of OCT\, OCT angiography\, mobile health testing\, tissue engineering\, and laser surgery. \n\nHis research\, funded by the NIH\, has been published in more than 300 peer-reviewed articles with over 55\,000 citations. Dr. Huang has received numerous awards throughout his career\, most notable being the Champalimaud Vision Award\, the Friedenwald Award from ARVO\, the Russ Prize from the National Academy of Engineering\, and the Visionary Award from the Greenberg Prize to End Blindness. He is a cofounder of Gobiquity\, maker of the GoCheck Kids app that has screened more than 5 million preschool children for amblyopia risk factors. Dr Huang also has a clinical practice in cornea and refractive surgery. He earned his BS and MS degrees in electrical engineering from MIT\, and MD-PhD degrees from the joint Harvard-MIT Health Sciences and Technology Program. He received ophthalmology residency training at the Doheny Eye Institute/University of Southern California and fellowship training in cornea and refractive surgery at Emory University. \n \n RSVP URL:https://doheny.org/event/distinguished-lecture-series-david-huang-md-phd/ LOCATION:Doheny Eye Institute\, 150 North Orange Grove Blvd. Rm 264\, Pasadena\, CA\, 91103\, United States CATEGORIES:Distinguished Lecture Series ATTACH;FMTTYPE=image/png:https://doheny.org/wp-content/uploads/2022/07/DLS-Huang-1.png ORGANIZER;CN="Janet DeMint & Kaustabh Ghosh%2C PhD":MAILTO:jdemint@doheny.org GEO:34.1488792;-118.1594996 X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Doheny Eye Institute 150 North Orange Grove Blvd. Rm 264 Pasadena CA 91103 United States;X-APPLE-RADIUS=500;X-TITLE=150 North Orange Grove Blvd. Rm 264:geo:-118.1594996,34.1488792 END:VEVENT END:VCALENDAR